Immunology articles within Nature Materials

Featured

  • Article |

    A nanoscale polymer layer formed by mucins at the surface of tumour cells protects them against immune cell attack. This shield can be circumvented through immune cell engineering, using chimeric antigen receptors to stimulate natural killer and T cells or by tethering glycocalyx-editing enzymes to immune cells.

    • Sangwoo Park
    • , Marshall J. Colville
    •  & Matthew J. Paszek

  • News & Views |

    Lipid nanodiscs carrying a potent STING agonist penetrate deep into solid tumours compared with gold-standard liposomes and enable long-term antitumour immunotherapy.

    • Ningqiang Gong
    •  & Michael J. Mitchell

  • Article
    | Open Access

    Here the authors investigate lipid nanodiscs as drug carriers for antitumour immunotherapy. They demonstrate that flexible lipid nanodiscs functionalized with STING-activating cyclic dinucleotides exhibit superior tumour penetration and tumour cell uptake compared with spherical liposomes, resulting in improved antitumour T-cell priming and tumour regression.

    • Eric L. Dane
    • , Alexis Belessiotis-Richards
    •  & Darrell J. Irvine

  • News & Views |

    A microporous annealed particle biomaterial has been developed to induce an immune response that can enhance wound healing and tissue repair.

    • Jessica L. Stelzel
    •  & Joshua C. Doloff

  • Review Article |

    This Review highlights the progress that has been made in the development of diagnostic tools for the detection of SARS-CoV-2 in the fight against COVID-19.

    • Bhavesh D. Kevadiya
    • , Jatin Machhi
    •  & Howard E. Gendelman

  • Article |

    Type-1 innate lymphoid cells have been shown to drive intestinal epithelial proliferation and extracellular matrix remodelling through TGF-β1 secretion, which could exacerbate inflammatory bowel disease comorbidities such as cancer and fibrosis.

    • Geraldine M. Jowett
    • , Michael D. A. Norman
    •  & Eileen Gentleman

  • Editorial |

    Within a few weeks of the novel coronavirus genome sequence being published, numerous therapies and vaccines have entered clinical trials with a few showing great promise in alleviating symptoms and accelerating recovery.

  • Comment |

    Consensus among experts is that only an effective COVID-19 vaccine will end the pandemic. This Comment focuses on how this pandemic has accelerated the development of vaccine platforms distinct from classical vaccines; these novel platforms may also increase the response time when new viruses emerge in the future.

    • Debby van Riel
    •  & Emmie de Wit

  • News & Views |

    In a murine model of acute colitis, hyaluronic acid–bilirubin-based nanomaterials have been shown to modulate immune response and the gut microbiome, as well as restore the epithelial barrier.

    • Ankur Singh

  • News & Views |

    Crystallized anti-inflammatory drugs have been shown to inhibit fibrosis on the surface of a number of devices over a long-term period following implantation in rodents and non-human primates.

    • Ruud A. Bank

  • News & Views |

    Microparticle debris from prosthetic implants has been shown to induce a type 2 inflammatory response through a Bruton’s tyrosine kinase-dependent signalling pathway.

    • Dimitri A. de Kouchkovsky
    • , Sourav Ghosh
    •  & Carla V. Rothlin

  • News & Views |

    A vaccine platform developed from a synthetic polymeric glyco-adjuvant and reversibly conjugated to an antigen was shown to target dendritic cells leading to cellular and humoral immune response against malaria.

    • Yvette van Kooyk

  • News & Views |

    Macrophage confinement reduces the ‘late’ inflammatory gene response to lipopolysaccharide through myocardin-related transcription factor, an actin-binding transcription factor.

    • Wendy F. Liu

  • News & Views |

    An amphipathic peptide has been engineered and is capable of penetrating the blood–brain barrier as well as possessing a potent antiviral activity against Zika and other mosquito-borne viruses.

    • Jing Zou
    •  & Pei-Yong Shi

  • Feature |

    Tumour heterogeneity and off-target toxicity are current challenges of cancer immunotherapy. Karine Dzhandzhugazyan, Per Guldberg and Alexei Kirkin discuss how epigenetic induction of tumour antigens in antigen-presenting cells may form the basis for multi-target therapies.

    • Karine N. Dzhandzhugazyan
    • , Per Guldberg
    •  & Alexei F. Kirkin

  • News & Views |

    A strategy to enhance antigen immunogenicity was developed by adsorption of polyethyleneimine on a mesoporous silica microrod vaccine for the presentation of tumour viruses and neoantigens, demonstrating their ability to drive anti-tumour immunity.

    • Cornelis J. M. Melief

  • Review Article |

    Immunotherapy offers a promising approach to treating a range of complications. This Review discusses strategies that employ bioengineering and immunological principles to develop engineered tissues for screening therapeutics and treating diseases.

    • Emily A. Gosselin
    • , Haleigh B. Eppler
    •  & Christopher M. Jewell

  • News & Views |

    An effective adjuvant for the induction of humoural and cellular immunity is achieved by a Pickering emulsion formulation that allows pliability and mobility of loaded antigens.

    • Herman F. Staats
    •  & David J. Burkhart

  • News & Views |

    DNA spacing within hexagonal bundles of DNA and polycationic peptides correlates with interferon production in dendritic cells.

    • William M. Gelbart

Browse broader subjects

Browse narrower subjects

Browse Immunology across other nature.com journals